All In Biotech

Drug Trial Radar · NCT06181292

Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to Assess the Safety and Immunogenicity of a Booster Vaccination With an Adapted Recombinant Protein RBD Fusion Homodimer Candidate Against SARS-CoV-2, in Adults Vaccinated Against COVID-19

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 913 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

913

Actual

Start

Nov 15, 2023

Primary completion

Jun 17, 2024

Study completion Jun 17, 2024

Sponsor

Lead sponsor
Hipra Scientific, S.L.UIndustry
Sponsor type
Industry
First posted
Dec 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein receptor binding domain (RBD) fusion homodimer of XBB.1.16 adapted candidate against SARS-CoV-2 developed by HIPRA (PHH-1V81).

Conditions

  • SARS-CoV2 Infection

Interventions

  • PHH-1V81Biological

    booster of PHH-1V81

  • Comirnaty Omicron XBB1.5Biological

    booster of Comirnaty Omicron XBB1.5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number, percentage and characteristics of solicited local and systemic AEs, unsolicited AEs, SAEs, AESIs and MAAEsTime frame: 0, 7, 14, 91 and 182 days post-vaccination
  2. Neutralising antibody titers of PHH-1V81 booster at Day 0 and 14Time frame: 0 and 14 days post-vaccination

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • Hospital HM Delfos

    Barcelona, Barcelona, Spain

  • CAP Centelles

    Centelles, Barcelona, Spain

  • Hospital Josep Trueta

    Girona, Girona, Spain

  • Hospital HM Sanchinarro

    Madrid, Madrid, Spain

  • Hospital Quironsalud Madrid

    Madrid, Madrid, Spain

  • Hospital HM Puerta del Sur

    Móstoles, Madrid, Spain

  • Hospital Regional de Málaga

    Málaga, Málaga, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Valencia, Spain

  • Hospital Universitario de Cruces

    Barakaldo, Vizcaya, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.